Sugammadex vs Neostigmine Reversal for Pediatric Appendectomy
Trial Summary
The trial information does not specify whether you need to stop taking your current medications.
Research suggests that sugammadex is generally safe for reversing neuromuscular blockade in pediatric patients, with a lower incidence of bradycardia (slow heart rate) compared to neostigmine. No significant differences were found in the incidences of other adverse events.
12345Sugammadex is unique because it works by directly encapsulating and removing the neuromuscular blocking agents rocuronium and vecuronium, leading to a faster and more complete reversal of muscle paralysis compared to neostigmine. Unlike neostigmine, sugammadex does not have cardiovascular, respiratory, or cholinergic side effects, making it a safer option for reversing neuromuscular blockade, especially in pediatric patients.
25678Eligibility Criteria
This trial is for children aged 2-17 undergoing laparoscopic appendectomy at Children's Healthcare of Atlanta-Egleston, diagnosed with acute appendicitis. Participants need a parent or guardian to understand and sign consent. It excludes those with kidney issues or allergies to Sugammadex or Neostigmine.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo laparoscopic appendectomy with neuromuscular reversal using either sugammadex or neostigmine/glycopyrrolate
Post-operative Monitoring
Participants are monitored for return of bowel function, tolerance of oral diet, and recovery from anesthesia
Follow-up
Participants are monitored for safety and effectiveness after treatment